News Perspectives

2 New Drugs Fight Resistant Skin Infections

Two new drugs offer a possible treatment option for skin infections that increasingly are able to resist current antibiotics. The New England Journal of Medicine published study results June 4. One study looked at dalbavancin, which recently was approved by the U.S. Food and Drug Administration. More than 1,300 people with bacterial skin infections were randomly divided into 2 groups. One group received dalbavancin intravenously (in a vein). It was given once a week for 2 weeks. The other group received a standard antibiotic, vancomycin. This was given in a vein twice a day for 3 days. Doctors then could prescribe antibiotic pills for the next 10 to 14 days. For about 80% of each group, treatment halted fever and the spread of infection within 3 days. The second study focused on oritavancin. This drug is not yet approved.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In